191 related articles for article (PubMed ID: 37109028)
1. Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review.
Yanagisawa T; Rajwa P; Quhal F; Kawada T; Bekku K; Laukhtina E; Deimling MV; Chlosta M; Karakiewicz PI; Kimura T; Shariat SF
J Pers Med; 2023 Apr; 13(4):. PubMed ID: 37109028
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
3. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
Rajwa P; Pradere B; Gandaglia G; van den Bergh RCN; Tsaur I; Shim SR; Yanagisawa T; Laukhtina E; Mori K; Mostafaei H; Quhal F; Bryniarski P; Compérat E; Roubaud G; Massard C; Merseburger AS; Leapman MS; Spratt DE; Saad F; Joniau S; D'Amico AV; Briganti A; Shariat SF; Ploussard G;
Eur Urol; 2022 Jul; 82(1):82-96. PubMed ID: 35465985
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular and Thromboembolic Events in Patients With Localized Prostate Cancer Receiving Intensified Neoadjuvant Androgen Deprivation: A Systematic Review and Meta-Analysis.
Felício de Campos E; Xavier CB; Queiroz MM; Firmino Lima Júnior N; Ilario EN; Coelho RF; Nahas WC; Bastos DA; Fontes Jardim DL
Clin Genitourin Cancer; 2024 Jun; 22(3):102088. PubMed ID: 38718699
[TBL] [Abstract][Full Text] [Related]
5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review.
Devos G; Vansevenant B; De Meerleer G; Clinckaert A; Devlies W; Claessens F; Graefen M; Steuber T; Briganti A; de la Taille A; Van Poppel H; Joniau S
World J Urol; 2021 Sep; 39(9):3177-3185. PubMed ID: 33580296
[TBL] [Abstract][Full Text] [Related]
7. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
[TBL] [Abstract][Full Text] [Related]
8. Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol.
Calleris G; Filleron T; Kesch C; Roubaud G; Pradère B; Cabarrou B; Malavaud B; Roupret M; Mourey L; Ploussard G
Eur Urol Oncol; 2024 Jun; 7(3):494-500. PubMed ID: 37806843
[TBL] [Abstract][Full Text] [Related]
9. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
Ciccarese C; Iacovelli R; Sternberg CN; Gillessen S; Tortora G; Fizazi K
Eur J Cancer; 2022 Sep; 173():276-284. PubMed ID: 35964470
[TBL] [Abstract][Full Text] [Related]
10. Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review.
Antonelli A; Palumbo C; Veccia A; Grisanti S; Triggiani L; Zamboni S; Furlan M; Simeone C; Magrini S; Berruti A
Minerva Urol Nefrol; 2018 Aug; 70(4):370-379. PubMed ID: 29392925
[TBL] [Abstract][Full Text] [Related]
11. Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis.
Katayama S; Mori K; Pradere B; Mostafaei H; Schuettfort VM; Quhal F; Motlagh RS; Laukhtina E; Grossmann NC; Rajwa P; Aydh A; König F; Mathieu R; Nyirady P; Karakiewicz PI; Nasu Y; Shariat SF
Scand J Urol; 2022 Apr; 56(2):85-93. PubMed ID: 35142251
[TBL] [Abstract][Full Text] [Related]
12. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
13. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
14. Do androgen-directed therapies improve outcomes in prostate cancer patients undergoing radical prostatectomy? A systematic review and meta-analysis.
Nayak AL; Flaman AS; Mallick R; Lavallée LT; Fergusson DA; Cagiannos I; Morash C; Breau RH
Can Urol Assoc J; 2021 Aug; 15(8):269-279. PubMed ID: 33443481
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
McKay RR; Ye H; Xie W; Lis R; Calagua C; Zhang Z; Trinh QD; Chang SL; Harshman LC; Ross AE; Pienta KJ; Lin DW; Ellis WJ; Montgomery B; Chang P; Wagner AA; Bubley GJ; Kibel AS; Taplin ME
J Clin Oncol; 2019 Apr; 37(11):923-931. PubMed ID: 30811282
[TBL] [Abstract][Full Text] [Related]
16. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
[TBL] [Abstract][Full Text] [Related]
17. Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled Trials.
Jones C; Gray S; Brown M; Brown J; McCloskey E; Rai BP; Clarke N; Sachdeva A
Eur Urol Oncol; 2024 Feb; ():. PubMed ID: 38383277
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials.
Zhuang J; Wang Y; Zhang S; Fu Y; Huang H; Lyu X; Zhang S; Marra G; Xu L; Qiu X; Guo H
Front Pharmacol; 2023; 14():1217303. PubMed ID: 37435500
[No Abstract] [Full Text] [Related]
19. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
